News

New Alzheimer’s target
Enlarge image

ScienceBelgium

New Alzheimer’s target

04.12.2012 - Scientists from VIB and KU Leuven have discovered a new target that could lay the foundations for a new approach to treat Alzheimer’s disease.

The research team, headed by Bart de Strooper from VIB, found that β-arrestin 2 blocks the plaque-form enzyme γ-secretase through interaction with the G protein–coupled receptors GPR3 and β2 -adrenergic receptor (Nature Medicine). Furthermore, they demonstrated that β-arrestin 2 was overexpressed in two independent cohorts of Alzheimer patients. Overexpression of the protein led to an increase in sticky amyloid-β (Aβ) peptides, called Aβ40 and Aβ42, which form the amyloid plaques that are associated with neurodegeneration. In contrast, genetic silencing of Arrb2, which encodes β-arrestin 2, reduced generation of Aβ in cell cultures and in knock-out mice for the Alzheimer regulator. The effect was mediated by direct binding to the Aph-1a subunit of the γ-secretase complex, which enzymatically generates the sticky Aβ peptides. Thus the scientists believe that inhibitors of β-arrestin 2 could block the generation of Aβ40 and Aβ42, in early stages of Alzheimer’s when no symptoms have yet emerged.

Currently there is no cure for the neurodegenerative disease. Many candidate drugs that target the γ-secretase complex fail because they also target proteins essential to life. The discovery from Leuven could form a target for a treatment against Alzheimer’s disease with fewer side effects and that suppresses the very first symptoms of the disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. This study thus provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer’s disease.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/new-alzheimers-target.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015